CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

CRISPR Therapeutics stock has had a strong shorter term recovery, yet longer term holders are still sitting on a large loss, and current valuation checks lean more toward an expensive reading than a clear bargain.

• The share price is down about 52.7% over 5 years, which means many longer term investors are still under water even after more recent gains.
• Fresh Phase 1a data for CTX310 presented at the ESC Congress 2026 may support confidence in CRISPR Therapeutics drug pipeline, while clinical and regulatory risk around turning that pipeline into sustained cash flows remains significant.
• The company screens as overvalued on market multiples and carries a mixed overall value score, so the broader checks point to a stock that is not clearly cheap or clearly expensive on fundamentals.

The issue now is whether CRISPR Therapeutics current share price fairly reflects the balance between its clinical progress and the risks that come with an early stage biotech pipeline.

Compare CRISPR Therapeutics with a hand picked list of other high potential healthcare and biotech stocks that also screen well on fundamentals using the solid balance sheet and fundamentals stocks screener (52 results).

Has CRISPR Therapeutics Run Too Far on Book Value?

For a business like CRISPR Therapeutics that is still reporting free cash flow losses, the P/B multiple gives a simple way to see how much investors are paying for each dollar of net assets. The stock trades on a P/B of about 3.2x, which is above the wider biotech industry average of roughly 2.5x, yet below a peer group average of about 7.0x.

Following the strong CTX310 Phase 1a data reported in 2026, this premium to the industry indicates that investors are already assigning a higher value to its balance sheet and pipeline potential. The shares do not appear to be the most highly valued within peers on this measure, but they tilt toward the more expensive side rather than standing out as a clear bargain.

On the P/B multiple, CRISPR Therapeutics stock currently appears more expensive than the broader biotech sector.

See what the numbers say about this price — find out in our valuation breakdown.

The CRISPR Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for CRISPR Therapeutics leaves off and spell out which assumptions on growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today's price, all hosted on the Community page. Each one turns fair value into a specific thesis about CRISPR Therapeutics' business that you can track over time to see how the story holds up against new information.

You can add your voice to the Simply Wall St community by sharing a Narrative on CRISPR Therapeutics that sets out your numbers based view on whether the recent CTX310 Phase 1a data and its durability story really support today's valuation. Put your thesis on record and track how it holds up as new trial results, regulatory updates and financial data emerge.

Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For CRISPR Therapeutics, the current market multiples lean toward an overvalued read, with investors already paying up for the drug platform and recent CTX310 progress. That does not rule out further upside, but it does mean expectations for successful development and commercialisation are already embedded in the price. The crux now is whether the pipeline can translate into durable, less risky cash flows quickly enough to justify this richer multiple, or whether ongoing clinical and regulatory uncertainty keeps pressure on the valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com